Showing 4841-4850 of 8787 results for "".
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas
- Lotrimin Taps WWE Superstar and Soles4Souls to Kick Foot Shame to the Curb and Encourage People to #GoWithConfidencehttps://practicaldermatology.com/news/lotrimin-taps-wwe-superstar-and-soles4souls-to-kick-foot-shame-to-the-curb-and-encourage-people-to-gowithconfidence/2460805/Lotrimin is teaming up with WWE Superstar The Miz to educate people on healthy feet habits and help people from all walks of life to #GoWithConfidence through a partnership with Soles4Souls – a nonprofit organization that turns unwanted shoes and clothing into opportunities for people in ne
- Chicago Dermatologist Dr. Amy S. Paller Wins American Skin Association’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/chicago-dermatologist-dr-amy-s-paller-wins-american-skin-associations-david-martin-carter-mentor-award/2460802/Amy S. Paller, MD of the Feinberg School of Medicine at Northwestern University in Chicago received the American Skin Association's David Martin Carter Mentor Award. For more than three decades, ASA's David Martin Carter Mentor Award has honored members of th
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pr
- FDA Accepts Amgen's sNDA for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/fda-accepts-amgens-snda-for-otezla-in-mild-to-moderate-pso/2460796/FDA has accepted for review the supplemental New Drug Application (sNDA) for Amgen's Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a PDUFA action date of
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog
- It’s Melanoma Monday! Focus on Preventionhttps://practicaldermatology.com/news/its-melanoma-monday-focus-on-prevention/2460792/With new data showing that one-third of Americans lack a basic understanding of skin cancer and sun protection, the American Academy of Dermatology’s annual Melanoma Monday takes on special significance.
- UCB: Bimekizumab PDUFA Date Set for Octoberhttps://practicaldermatology.com/news/ucb-bimekizumab-pdufa-set-for-october/2460787/The FDA's Prescription Drug User Fee Act (PDUFA) date for UCB’s Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is October 15, 2021, UCB has indicated. In a
- Pulse Biosciences Survey: Clearing Pigmented Lesions is No. 1 Priority for Manyhttps://practicaldermatology.com/news/pulse-biosciences-survey-clearing-pigmented-lesions-is-no-1-priority-for-many/2460786/A majority of patients with unwanted benign lesions are interested in a new procedure to clear these lesions, according to a new survey by Pulse Biosciences that was presented at the American Academy of Dermatology (AAD) Virtual Annual Meeting. A diverse sample of 405 aesthetic patients
- Minimizing Risks of Cosmetic Procedures in Patients with Darker Skin Typeshttps://practicaldermatology.com/news/minimizing-risks-of-cosmetic-procedures-in-patients-with-darker-skin-types/2460784/With cosmetic procedures in high demand during the pandemic, Cedars-Sinai dermatologist Jasmine Obioha, MD, has seen an unfortunate side effect: botched treatments for patients of color. When performed improperly, procedures such as chemical peels and laser hair removal can inflame and